MYQORZO (Aficamten) was approved by the FDA for obstructive hypertrophic cardiomyopathy (MAPLE-HCM sNDA, aficamten vs metoprolol); the approval was announced on November 16, 2026.
Verified against: FDA action day November 13, 2026 (NDA 219083 S-002) · Announcement November 16, 2026 (Cytokinetics press release) · Goal date November 14, 2026 (CYTOKINETICS INC 8-K).
This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 1:24 AM ET (public commit ce46f16). Dates on this page are the FDA's and the sponsor's; this line is ours.
Cytokinetics announced on November 16, 2026 that the FDA approved its sNDA adding Phase 3 MAPLE-HCM data (aficamten versus metoprolol) to the MYQORZO prescribing information; the indication is unchanged.
The PDUFA goal date was November 14, 2026 (a Saturday). The FDA's own record dates the action November 13, 2026, 1 day before the goal date; Cytokinetics announced it on November 16, 2026.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Primary source: Cytokinetics press release, November 16, 2026
FDA record of the action: the FDA approved on November 13, 2026, per NDA 219083 S-002 (Drugs@FDA). The sponsor announced it on November 16, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Avoro Capital Advisors | 4,900,000 | $323.0 million | filed November 16, 2026 |
| RTW Investments | 2,862,003 | $188.6 million | filed November 16, 2026 |
| Baker Bros. Advisors | 211,267 | $13.9 million | filed November 16, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Yes. The FDA approved the application for MYQORZO (aficamten) MAPLE-HCM sNDA on November 13, 2026, per the FDA's own record. The company announced it on November 16, 2026. The primary source is linked on this page.
MYQORZO (aficamten) MAPLE-HCM sNDA is a Cytokinetics Inc (CYTK) program. The FDA decision came on November 13, 2026; the company's own announcement is linked on this page.
CYTK moved -5.3%, measured as the 2026-11-16 close (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.